Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
Conditions
Keywords
prostate cancer, Castration-Resistant Prostate Cancer, Cabazitaxel
Brief summary
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using abiraterone acetate and antiandrogen therapy may fight prostate cancer by lowering and/or blocking the use of androgens by the tumor cells. Drugs used in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abiraterone acetate and antiandrogen therapy with or without cabazitaxel and prednisone may help kill more tumor cells.
Detailed description
PRIMARY OBJECTIVES: I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with castration-resistant prostate cancer (CRPC) that have previously received docetaxel and androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) can improve progression-free survival (PFS) compared to abiraterone acetate alone. SECONDARY OBJECTIVES: I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can increase the percentage of change in prostate-specific antigen (PSA) from baseline to week 12 of treatment as well as the maximum decline in PSA that occurs at any point after treatment compared to abiraterone acetate alone. II. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel for HSPC can prolong time to PSA progression compared to abiraterone acetate alone. III. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel for HSPC can improve radiographic response (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1) compared to abiraterone acetate alone. IV. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can prolong the overall survival (OS) compared to abiraterone acetate alone. V. To assess safety and tolerability of the combination of 6 cycles of cabazitaxel and abiraterone acetate. TERTIARY OBJECTIVES: I. To examine whether patients with circulating tumor cells (CTCs) positive for AR-V7 at baseline have a longer radiographic or clinical PFS to the combination of cabazitaxel and abiraterone acetate vs. abiraterone acetate alone. II. To examine whether the addition of cabazitaxel to abiraterone acetate can change the AR-V7 status of patients who are positive at study entry. III. To examine whether the addition of cabazitaxel to abiraterone acetate has any impact on future development of AR-V7 positivity at the time of disease progression. IV. To assess if the changes in total tumor burden from baseline to week 12 as assessed with sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) will differ between two arms. V. To correlate total tumor burden at the baseline as assessed with NaF PET/CT with the PFS. VI. To correlate heterogeneity of response from baseline to week 12 as assessed with NaF PET/CT with the PFS. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive abiraterone acetate orally (PO) once daily (QD) on days 1-21, prednisone PO twice daily (BID) on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel intravenously (IV) over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, or surgical castration with bilateral orchiectomy. ARM B: Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy. After completion of study treatment, patients are followed up every 3 or 6 months and then annually for up to 5 years.
Interventions
DRUGAbiraterone Acetate
Given PO
DRUGAndrogen deprivation therapy
Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist or surgical castration with bilateral orchiectomy.
DRUGCabazitaxel
Given IV
DRUGPrednisone
Given PO
Sponsors
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) * Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer * Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT/magnetic resonance imaging \[MRI\] of abdomen/pelvis, bone scintigraphy or NaF PET/CT) * Ability to swallow abiraterone acetate tablets as a whole * All patients must be receiving standard of care androgen deprivation treatment (surgical castration versus LHRH agonist or antagonist treatment); subjects receiving LHRH agonist or antagonist must continue treatment throughout the time on this study * Patients must have castrate serum level of testosterone of \< 50 ng/dL (\< 1.73 nmol/L) * Patients must have progressive disease while receiving androgen deprivation therapy defined by any one of the following as per the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria for PSA, measurable disease or non-measurable (bone) disease during treatment with ADT: * PSA: At least two consecutive rises in serum PSA, obtained at a minimum of 1-week intervals, with the final value \>= 1.0 ng/mL, confirmed \<=4 weeks prior to randomization * Measurable disease (by RECIST 1.1): \> 20% increase in the sum of the longest diameters of all measurable lesions or the development of new measurable lesions; the short axis of a target lymph node must be more than 15 mm to be assessed for change in size * Non-measurable (bone) disease: The appearance of two or more new areas of uptake on bone scan (or NaF PET/CT) consistent with metastatic disease compared to previous imaging during castration therapy; the increased uptake of pre-existing lesions on bone scan will not be taken to constitute progression, and ambiguous results must be confirmed by other imaging modalities (e.g. X-ray, CT or MRI). Clinical decisions about response or progression will be based on CT and bone scans. * Patients may or may not have been treated previously with a nonsteroidal antiandrogen, such as flutamide, bicalutamide or nilutamide; for patients previously treated with an antiandrogen, they must be off treatment for at least 4 weeks (for flutamide) or 6 weeks (for bicalutamide or nilutamide) prior to registration and must have shown PSA progression after discontinuing the anti-androgen * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Hemoglobin (HgB) \>= 9.0 gr/dL * Platelets \>= 100,000/mm\^3 * Creatinine \< 2.0 mg/dL * Patients must be informed of the experimental nature of the study and its potential risks, and must sign an Institutional Review Board (IRB)-approved written informed consent form indicating such an understanding * Patients with resected or irradiated brain metastases or those treated with stereotactic radiation therapy are eligible to enroll, provided that they do not require treatment with steroids that exceeds 10 mg of prednisone daily or equivalent * Sexually active males must use an accepted and effective method of double barrier contraception or abstain from sexual intercourse for the duration of their participation in the study and for 26 weeks after the last dose of study drug * NaF PET/CT OPTIONAL SUB-STUDY ELIGIBILITY CRITERIA * Ability to lie still for imaging * Weight =\< 300 lbs (pounds) * Metastatic disease confined predominantly to the bones
Exclusion criteria
* Any prior chemotherapy or androgen receptor (AR)-directed therapy for CRPC, (e.g. docetaxel, cabazitaxel, mitoxantrone, abiraterone acetate, ketoconazole, or enzalutamide); previous treatment with radium-223 or sipuleucel-T is allowed * Pure small cell or other variant (non-adenocarcinoma) prostate cancer histology for which treatment with abiraterone would not be considered appropriate * Patients may not be receiving other therapeutic investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy; concurrent treatment with agents to prevent skeletal-related events (such as zoledronic acid or denosumab) will be allowed as long as it was initiated prior to study entry or there are plans to initiate it after cycle 2 day 1. * Any medical condition for which prednisone (corticosteroid) is contraindicated * Total bilirubin \> upper limit of normal (ULN) (NOTE: in subjects with Gilbert's syndrome, if total bilirubin is \> ULN, measure direct and indirect bilirubin and if direct bilirubin is within normal range, subject may be eligible) * Alanine (ALT) or aspartate (AST) aminotransferase \> 1.5 x ULN * Active infection requiring treatment with antibiotics * History of adrenal insufficiency or hypoaldosteronism * Myocardial infarction or arterial thrombotic event within 6 months of randomization, heart failure of New York Heart Association class II or higher, uncontrolled angina, severe uncontrolled ventricular arrhythmia * External beam radiation therapy within 2 weeks of registration * Prior history of allergic reactions to G-CSF * Prior history of allergic reactions to docetaxel and/or to medications formulated with polysorbate 80 * History of active malignancy; patients with a history of cancer that has been adequately treated and are free of disease recurrence for 3 years or more are allowed to participate; patients with non-melanoma skin cancers or carcinoma in situ of the bladder that have been adequately excised are eligible to participate * Life expectancy of \< 12 months at screening * Grade \>= 2 neuropathy * Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg). Patients with a history of hypertension are allowed to enroll provided blood pressure is controlled with anti-hypertensive treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years | PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change in PSA From Baseline to 12 Weeks | Assessed at baseline and 12 weeks | PSA was assessed at baseline and 12 weeks. Percent change in PSA from baseline to 12 weeks is calculated as follows: ((PSA at 12 weeks - baseline PSA)/baseline PSA) x 100 |
| Maximum Percent Change in PSA From Baseline While on Treatment | Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years | Maximum percent change in PSA from baseline while on treatment was calculated as follows: ((PSA nadir while on treatment - baseline PSA)/baseline PSA) x 100 |
| Time to PSA Progression | Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years | Time to PSA progression was defined as the time from randomization to PSA progression or date of last PSA assessment. Patients who experienced radiographic progression without documented PSA progression were counted as having an event. |
| Proportion of Patients With Radiographic Response | Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years | Radiographic response was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and was defined as either complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. All (non-target) lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
| Overall Survival (OS) | Assessed every 3 month is patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry, and then annually for up to year 5 | Overall survival was defined as the time from randomization until death or date last known alive. |
Countries
Puerto Rico, United States
Contacts
PRINCIPAL_INVESTIGATORChristos Kyriakopoulos
ECOG-ACRIN Cancer Research Group
Participant flow
Recruitment details
This study was activated on February 8, 2018 and closed to accrual on March 26, 2021, after accrual of 223 patients.
Participants by arm
| Arm | Count |
|---|---|
| Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy. | 111 |
| Arm B (Abiraterone Acetate, Prednisone) Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy. | 112 |
| Total | 223 |
Baseline characteristics
| Characteristic | Arm B (Abiraterone Acetate, Prednisone) | Total | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) |
|---|---|---|---|
| Age, Continuous | 66 years | 64 years | 63 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 5 Participants | 10 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 105 Participants | 209 Participants | 104 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 22 Participants | 42 Participants | 20 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 12 Participants | 7 Participants |
| Race (NIH/OMB) White | 81 Participants | 165 Participants | 84 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 112 Participants | 223 Participants | 111 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 80 / 111 | 79 / 112 |
| other Total, other adverse events | 101 / 109 | 80 / 108 |
| serious Total, serious adverse events | 46 / 109 | 31 / 108 |
Outcome results
Primary
Progression-free Survival (PFS)
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment.
Time frame: Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
Population: All randomized patients are included in this analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Progression-free Survival (PFS) | 14.9 months |
| Arm B (Abiraterone Acetate, Prednisone) | Progression-free Survival (PFS) | 9.9 months |
p-value: 0.049Log Rank
Secondary
Maximum Percent Change in PSA From Baseline While on Treatment
Maximum percent change in PSA from baseline while on treatment was calculated as follows: ((PSA nadir while on treatment - baseline PSA)/baseline PSA) x 100
Time frame: Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years
Population: Patients who started protocol therapy are included in this analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Maximum Percent Change in PSA From Baseline While on Treatment | -94.0 percentage of change in PSA |
| Arm B (Abiraterone Acetate, Prednisone) | Maximum Percent Change in PSA From Baseline While on Treatment | -67.7 percentage of change in PSA |
Secondary
Overall Survival (OS)
Overall survival was defined as the time from randomization until death or date last known alive.
Time frame: Assessed every 3 month is patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry, and then annually for up to year 5
Population: All randomized patients are included in this analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Overall Survival (OS) | 25.0 months |
| Arm B (Abiraterone Acetate, Prednisone) | Overall Survival (OS) | 26.9 months |
Secondary
Percent Change in PSA From Baseline to 12 Weeks
PSA was assessed at baseline and 12 weeks. Percent change in PSA from baseline to 12 weeks is calculated as follows: ((PSA at 12 weeks - baseline PSA)/baseline PSA) x 100
Time frame: Assessed at baseline and 12 weeks
Population: Patients who started protocol therapy and had both baseline PSA as well as 12-week PSA available are included in this analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Percent Change in PSA From Baseline to 12 Weeks | -87.5 percentage of change in PSA |
| Arm B (Abiraterone Acetate, Prednisone) | Percent Change in PSA From Baseline to 12 Weeks | -65.9 percentage of change in PSA |
Secondary
Proportion of Patients With Radiographic Response
Radiographic response was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and was defined as either complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. All (non-target) lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
Population: All randomized patients are included in this analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Proportion of Patients With Radiographic Response | 0.117 Proportion of participants |
| Arm B (Abiraterone Acetate, Prednisone) | Proportion of Patients With Radiographic Response | 0.080 Proportion of participants |
Secondary
Time to PSA Progression
Time to PSA progression was defined as the time from randomization to PSA progression or date of last PSA assessment. Patients who experienced radiographic progression without documented PSA progression were counted as having an event.
Time frame: Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years
Population: All randomized patients are included in this analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Time to PSA Progression | 10.0 months |
| Arm B (Abiraterone Acetate, Prednisone) | Time to PSA Progression | 6.1 months |
Other Pre-specified
Androgen-Receptor Splice Variant 7 Messenger RNA (AR-V7) Status
The presence of AR-V7 in circulating tumor cells was assessed at baseline and Cycle 5 Day 1.
Time frame: Assessed at baseline and Cycle 5 Day 1
Other Pre-specified
Association Between PFS and Total Tumor Burden at the Baseline as Assessed With NaF PET/CT
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and total tumor burden at baseline as assessed with NaF PET/CT will be evaluated.
Time frame: Assessed at baseline, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
Other Pre-specified
Changes in Total Tumor Burden From Baseline to Week 12 as Assessed With NaF PET/CT
Total tumor burden was assessed by NaF PET/CT at baseline and 12 weeks. The changes in total tumor burden will be compared between the two arms.
Time frame: Assessed at baseline and 12 weeks
Other Pre-specified
Development of AR-V7 Positivity at the Time of Disease Progression
The presence of AR-V7 in circulating tumor cells was assessed at baseline and disease progression.
Time frame: Assessed at baseline and disease progression
Other Pre-specified
PFS Among Patients With Circulating Tumor Cells (CTCs) Positive for Androgen-receptor Splice Variant 7 Messenger RNA (AR-V7) at Baseline
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. AR-V7 was assessed at baseline.
Time frame: Assessed at baseline, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
Other Pre-specified
The Association Between PFS and the Heterogeneity of Response From Baseline to Week 12 as Assessed With NaF PET/CT
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and the heterogeneity of response from baseline to week 12 as assessed with NaF PET/CT will be evaluated.
Time frame: Assessed at baseline, 12 weeks, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years